Literature DB >> 33738533

Transcriptional and epigenetic regulation of PD-1 expression.

Zengde Chi1, Yan Lu2,3, Yinlong Yang4, Bingqing Li2, Peiyuan Lu5,6.   

Abstract

Programmed cell death-1 (PD-1) is a co-inhibitory receptor that plays important roles in regulating T cell immunity and peripheral tolerance. PD-1 signaling prevents T cells from overactivation during acute infections, but it maintains T cell exhaustion during chronic infections. Tumor cells can exploit the PD-1 signaling pathway to evade antitumor immune responses. The PD-1 signaling pathway is also essential for maintaining peripheral tolerance and prevention of autoimmunity. PD-1 expression is strictly and differentially regulated by diverse mechanisms in immune cells. It is activated and repressed by distinct transcription factors in different circumstances. Moreover, epigenetic mechanisms are also involved in regulating PD-1 expression. In this review, we summarize the knowledge of the transcriptional and epigenetic regulation of PD-1 expression during different immune responses.

Entities:  

Keywords:  Epigenetic regulation; Gene expression; PD-1; Transcriptional regulation

Mesh:

Substances:

Year:  2021        PMID: 33738533     DOI: 10.1007/s00018-020-03737-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  69 in total

Review 1.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Overcoming T cell exhaustion in infection and cancer.

Authors:  Kristen E Pauken; E John Wherry
Journal:  Trends Immunol       Date:  2015-03-18       Impact factor: 16.687

Review 3.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

Review 4.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Authors:  Vassiliki A Boussiotis
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

Review 5.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

Review 6.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 7.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 8.  The diverse functions of the PD1 inhibitory pathway.

Authors:  Arlene H Sharpe; Kristen E Pauken
Journal:  Nat Rev Immunol       Date:  2017-11-13       Impact factor: 53.106

Review 9.  PD-1 and PD-1 ligands: from discovery to clinical application.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2007-07-02       Impact factor: 4.823

Review 10.  The Role of PD-1 in Acute and Chronic Infection.

Authors:  Jil M Jubel; Zachary R Barbati; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

View more
  3 in total

1.  Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4.

Authors:  Jing Guo; Zhonghui Xue; Lie Wang
Journal:  Cell Mol Immunol       Date:  2022-05-20       Impact factor: 22.096

2.  In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.

Authors:  Dario Righelli; Crescenzo D'Alterio; Caterina Ieranò; Maria Napolitano; Luigi Portella; Giuseppina Rea; Federica Auletta; Sara Santagata; Anna Maria Trotta; Giuseppe Guardascione; Federica Liotti; Nella Prevete; Piera Maiolino; Antonio Luciano; Antonio Barbieri; Annabella Di Mauro; Cristin Roma; Riziero Esposito Abate; Fabiana Tatangelo; Roberto Pacelli; Nicola Normanno; Rosa Marina Melillo; Stefania Scala
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

Review 3.  Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy.

Authors:  Hongzhen Cai; Man Li; Ruiyi Deng; Mopei Wang; Yanyan Shi
Journal:  Biomark Res       Date:  2022-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.